Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lotiglipron in T2DM and Obesity
NCT05579977Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of lotiglipron in type 2 diabetes mellitus (T2DM), obesity, sponsored by Pfizer. Started Oct 2022; status: terminated.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05579977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579977.